Clinical trials: Non-small-cell Lung Cancer (NSCLC)
Progression Free Survival
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in non-small cell lung cancer.
- Trial name
- NCT02959749
- Testing
- Osimertinib, docetaxel, bevacizumab
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Qingdao Central Hospital
Lung Cancer (NSCLC)
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
The study aims to enroll 500 non-small cell lung cancer patients at various stages and to employ this technology for CTC detection, with subsequent cytomorphological and chromosomal analysis of the isolated CTCs, and…
- Trial name
- NCT07186855
- Testing
- Blood Sample Collection for CTC Detection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
- Trial name
- GALAXY (NCT01348126)
- Testing
- Docetaxel, Combination of ganetespib and docetaxel
- Where
- 53 sites in United States, Belgium and 11 more
- Volunteers
- 385 people
- Sponsor
- Synta Pharmaceuticals Corp.
Advanced Cancer
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of…
- Trial name
- NCT00106626
- Testing
- vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Circulating DNA in Surgically Treated NSCLC
The investigators will prospectively recruit 100 NSCLC patients. The cfDNA samples will be gathered before the surgery and postoperatively 4-6 weeks after surgery and at 6 and 12 months follow-up visits.
- Trial name
- NCT04037150
- Testing
- Circulating tumor DNA
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Non-small Cell Lung Cancer
Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
Concurrent chemoradiotherapy is the standard treatment for locally advanced, unresectable non-small cell lung cancer, but carries a risk of radiation pneumonitis of approximately 30%, and is associated with a decline in pulmonary…
- Trial name
- FLAIR (NCT02002052)
- Testing
- Concurrent platinum-based chemotherapy, Standard Radiotherapy, 60 Gy in 30 fractions., Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of onalespib lactate when given together with erlotinib hydrochloride and to see how well they work in treating patients with EGFR-mutant non-small cell lung cancer…
- Trial name
- NCT02535338
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Onalespib Lactate
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Obstructive Sleep Apnea, Non-small Cell Lung Cancer
Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer
This prospective, observational cohort study aims to explore the influence of obstructive sleep apnea(OSA) on the efficacy of PD-1-based immunotherapy in patients with non-small cell lung cancer(NSCLC).
- Trial name
- NCT04743752
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl.
- Trial name
- NAUTIC (NCT06494540)
- Where
- 30 sites in Germany
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
- Trial name
- ATHENA (NCT04322617)
- Testing
- Anlotinib plus the same Immune Checkpoint Inhibitors., Anlotinib plus the new Immune Checkpoint Inhibitors., Anlotinib
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Hunan Province Tumor Hospital
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency
- Trial name
- NCT02983578
- Testing
- Danvatirsen, Durvalumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003089
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-Small Cell Lung Cancer
A Study of Prevalence of EGFR Mutations in Participants With NSCLC
This is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in participants diagnosed with non-squamous non-small cell lung cancer…
- Trial name
- NCT02695849
- Where
- 2 sites in Jordan
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers.
- Trial name
- CHIARA (NCT01562015)
- Testing
- Ganetespib
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Synta Pharmaceuticals Corp.
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab…
- Trial name
- PACIFIC-9 (NCT05221840)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 202 sites in United States, Australia and 18 more
- Volunteers
- 1,051 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00564733
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Non-small Cell Lung Cancer
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.
- Trial name
- NCT03169738
- Testing
- avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.